Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Preventive radiation may stop bone events before they start — a trial puts it to the test

NCT ID NCT07733193

Disease control Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether giving radiation therapy early — before symptoms appear — can reduce the risk of bone complications (like fractures or spinal cord pressure) in people with solid tumors that have spread to the bone. Participants have bone lesions that are considered at intermediate risk for such events. Half will receive preventive radiation, while the other half will receive standard care and be monitored closely. The goal is to see if early treatment can prevent these painful and serious events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prophylactic radiation therapy
What this could lead to
If it works, this could establish a new standard for preventing painful bone complications in patients with cancer that has spread to the bones.
What could go wrong
This is a phase 3 trial, but the benefit of preventive radiation in intermediate-risk patients is unproven, and radiation itself carries risks like fatigue or local side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 154 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women, 18 years of age or older * Patients with solid cancer and bone metastases * Patients with bone lesions considered to be at intermediate risk for skeletal-related events (SINS score between 7 and 12, Mirels 8) or patients with lesions accompanied by Grade 1 epiduritis (Bilsky) * Enrolled in or covered by a social insurance program * Patients with an estimated life expectancy of more than 6 months Exclusion Criteria: * Hematologic disease * Patients with a lesion at high risk for skeletal-related events (SINS score of 13 or higher, MIRELS score of 9 or higher, or a multidisciplinary team (MDT) recommendation that surgery is necessary) * Patients with pain secondary to bone lesions requiring radiation therapy * Contraindication to radiation therapy due to a history of radiation therapy at the same site or a condition contraindicating radiation therapy * Pregnant or breastfeeding women * Contraindication to MRI in cases of spinal lesions; contrast-enhanced CT scan * Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographic issues, etc.) * Patients under legal guardianship or conservatorship * Patients classified as WHO 3 or 4

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic carcinoma in the bone Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone metastases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, France

  • Institut de Cancérologie de Lorraine

    Nancy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.